​

Solventum (SOLV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SOLV Stock Forecast

Solventum (SOLV) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $90.00, with a high of $103.00 and a low of $77.00. This represents a 26.90% increase from the last price of $70.92.

$50 $61 $72 $83 $94 $105 High: $103 Avg: $90 Low: $77 Last Closed Price: $70.92

SOLV Stock Rating

Solventum stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (42.86%), 3 Hold (42.86%), 1 Sell (14.29%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 3 3 Strong Sell Sell Hold Buy Strong Buy

SOLV Price Target Upside V Benchmarks

TypeNameUpside
StockSolventum26.90%
SectorHealthcare Stocks 15.45%
IndustryMedical Care Facilities Stocks12.74%

Price Target Trends

1M3M12M
# Anlaysts115
Avg Price Target$77.00$77.00$81.40
Last Closing Price$70.92$70.92$70.92
Upside/Downside8.57%8.57%14.78%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 252281-13
Sep, 252261-11
Aug, 25226-111
Jul, 25218-112
Jun, 25118-111
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 01, 2025Kevin CaliendoUBS$77.00$73.005.48%8.57%
Jul 15, 2025Patrick WoodMorgan Stanley$103.00$73.6839.79%45.23%
Mar 03, 2025Mizuho Securities$82.00$80.162.30%15.62%
Feb 28, 2025Wells Fargo$75.00$79.75-5.96%5.75%
Dec 03, 2024Steven ValiquetteMizuho Securities$70.00$72.28-3.15%-1.30%
Oct 07, 2024Rick WiseStifel Nicolaus$82.00$66.2923.70%15.62%
Oct 07, 2024Jason BednarPiper Sandler$71.00$67.744.81%0.11%
Jul 15, 2024Patrick WoodMorgan Stanley$55.00$49.0012.24%-22.45%
May 30, 2024David RomanGoldman Sachs$54.00$59.72-9.58%-23.86%
Apr 09, 2024Patrick WoodMorgan Stanley$70.00$65.526.84%-1.30%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2025UBSNeutralinitialise
Sep 11, 2025JefferiesHoldinitialise
Aug 08, 2025Piper SandlerOverweightOverweighthold
Jul 15, 2025Morgan StanleyEqual-WeightOverweightupgrade
Jun 06, 2025KeyBancSector Weightinitialise
May 19, 2025Piper SandlerNeutralOverweightupgrade
Oct 07, 2024Piper SandlerNeutralinitialise
Sep 27, 2024BTIGNeutralNeutralhold
Sep 26, 2024Wolfe ResearchPeer Performinitialise
Sep 05, 2024BTIGNeutralinitialise

Financial Forecast

EPS Forecast

$2 $3 $4 $5 $6 $7 $8 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.79$2.77----
Avg Forecast-$6.59$5.50$5.87$6.19$6.30
High Forecast-$6.62$5.76$6.35$6.26$6.37
Low Forecast-$6.57$5.23$5.29$6.13$6.23
Surprise %--57.97%----

Revenue Forecast

$8B $8B $8B $8B $9B $9B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.20B$8.25B----
Avg Forecast$8.20B$8.23B$8.26B$8.41B$8.48B$8.57B
High Forecast$8.27B$8.31B$8.33B$8.41B$8.48B$8.65B
Low Forecast$8.13B$8.22B$8.22B$8.40B$8.48B$8.50B
Surprise %-0.27%----

Net Income Forecast

$450M $630M $810M $990M $1B $1B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.35B$479.00M----
Avg Forecast-$1.14B$947.53M$1.00B$1.07B$1.09B
High Forecast-$1.14B$993.31M$1.09B$1.08B$1.10B
Low Forecast-$1.13B$901.75M$911.80M$1.06B$1.08B
Surprise %--57.89%----

SOLV Forecast FAQ

Is Solventum stock a buy?

Solventum stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Solventum is a favorable investment for most analysts.

What is Solventum's price target?

Solventum's price target, set by 7 Wall Street analysts, averages $90 over the next 12 months. The price target range spans from $77 at the low end to $103 at the high end, suggesting a potential 26.90% change from the previous closing price of $70.92.

How does Solventum stock forecast compare to its benchmarks?

Solventum's stock forecast shows a 26.90% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical care facilities stocks industry (12.74%).

What is the breakdown of analyst ratings for Solventum over the past three months?

  • October 2025: 15.38% Strong Buy, 15.38% Buy, 61.54% Hold, 7.69% Sell, 0% Strong Sell.
  • September 2025: 18.18% Strong Buy, 18.18% Buy, 54.55% Hold, 9.09% Sell, 0% Strong Sell.
  • August 2025: 18.18% Strong Buy, 18.18% Buy, 54.55% Hold, 0% Sell, 9.09% Strong Sell.

What is Solventum’s EPS forecast?

Solventum's average annual EPS forecast for its fiscal year ending in December 2025 is $5.5, marking a 98.56% increase from the reported $2.77 in 2024. Estimates for the following years are $5.87 in 2026, $6.19 in 2027, and $6.3 in 2028.

What is Solventum’s revenue forecast?

Solventum's average annual revenue forecast for its fiscal year ending in December 2025 is $8.26B, reflecting a 0.10% increase from the reported $8.25B in 2024. The forecast for 2026 is $8.41B, followed by $8.48B for 2027, and $8.57B for 2028.

What is Solventum’s net income forecast?

Solventum's net income forecast for the fiscal year ending in December 2025 stands at $947.53M, representing an 97.81% increase from the reported $479M in 2024. Projections indicate $1B in 2026, $1.07B in 2027, and $1.09B in 2028.